RA0221

antibody from Oursmab

Targeting: ERBB2 CD340, HER-2, HER2, NEU, NGL

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0221

Provider

Oursmab

Product name

Cinrebafusp (Biosimilar Reference Antibody) (ERBB2)

Antibody type

Monoclonal

Description

Cinrebafusp alfa (PRS-343) is an investigational, high-affinity bispecific antibody developed by Pieris Pharmaceuticals using its proprietary Anticalin? platform technology. It is designed for the treatment of HER2-positive solid tumors. The drug functions by simultaneously targeting two distinct molecules: the tumor-associated antigen HER2 on cancer cells and the co-stimulatory receptor CD137 (4-1BB) on immune cells. This unique design aims to conditionally activate T cells specifically within the tumor microenvironment, thereby enhancing anti-tumor immunity while potentially minimizing systemic toxicity. The use of the Anticalin scaffold also contributes to a reduced risk of immunogenicity.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.